Editas Medicine, Inc.

Editas Medicine, Inc. (www.editasmedicine.com) is a clinical-stage gene editing company. The Company is focused on developing transformative gene-editing medicines to treat a range of serious diseases. It operates through the developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The Company is focused on both in vivo gene-editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body and ex vivo gene-edited cell medicines, in which cells are edited with its technology.

• Editas Medicine, Inc.